LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Aandelen Lijst・Bridgebio Pharma Inc

Bridgebio Pharma Inc

Gesloten

SectorGezondheidszorg

66.69 -1.05

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

66.16

Max

67.2

Belangrijke statistieken
By Trading Economics
Inkomsten	-7.5M -190M
Verkoop	33M 154M
Winstmarge	-123.403
Werknemers	834
EBITDA	-6.9M -180M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+57.86% upside

Dividenden
By Dow Jones
Volgende Winsten	4 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	361M 13B
Vorige openingsprijs	67.74
Vorige sluitingsprijs	66.69

Nieuwssentiment

By Acuity

50%

159 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

34.71 / 36.9 Steun & Weerstand

Bridgebio Pharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 mei 2026, 23:47 UTC

Marktinformatie

Gold Falls on Renewed Inflation Concerns -- Market Talk

10 mei 2026, 23:44 UTC

Marktinformatie

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

10 mei 2026, 23:38 UTC

Marktinformatie

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

10 mei 2026, 23:14 UTC

Marktinformatie

Australia's Political Map Continues to Be Redrawn -- Market Talk

10 mei 2026, 22:22 UTC

Acquisities, Fusies, Overnames

Elevra Lithium: Expects Deal to Close in 1Q FY27

10 mei 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

10 mei 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

10 mei 2026, 10:21 UTC

Winsten

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

9 mei 2026, 06:05 UTC

Winsten

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8 mei 2026, 23:55 UTC

Winsten

Review & Preview: Still Going Strong -- Barrons.com

8 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 mei 2026, 20:49 UTC

Winsten

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 mei 2026, 20:25 UTC

Winsten

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mei 2026, 19:43 UTC

Winsten

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 mei 2026, 19:43 UTC

Winsten

Cencosud 1Q Net $115M

8 mei 2026, 19:20 UTC

Marktinformatie

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 mei 2026, 19:18 UTC

Winsten

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 mei 2026, 19:16 UTC

Winsten

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mei 2026, 19:08 UTC

Winsten

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mei 2026, 19:05 UTC

Winsten

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 mei 2026, 19:02 UTC

Marktinformatie

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 mei 2026, 18:51 UTC

Winsten

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 mei 2026, 18:49 UTC

Winsten

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mei 2026, 18:41 UTC

Winsten

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 mei 2026, 17:38 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 mei 2026, 17:14 UTC

Winsten

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 mei 2026, 17:04 UTC

Marktinformatie

Zcash Caps Off Parabolic Week -- Market Talk

8 mei 2026, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

8 mei 2026, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 mei 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Bridgebio Pharma Inc Prognose

Koersdoel

By TipRanks

57.86% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 106.38 USD 57.86%

Hoogste 157 USD

Laagste 81 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bridgebio Pharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

18 ratings

Buy

Hold

Sell

Gebaseerd op 18 analisten die aandelenratings hebben gegeven aan Bridgebio Pharma Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

34.71 / 36.9Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

159 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.